Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Silverberg Bernstein Capital Management LLC

Silverberg Bernstein Capital Management LLC cut its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 0.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 68,440 shares of the company’s stock after selling 600 shares during the period. Teva Pharmaceutical Industries makes up about 1.3% of Silverberg Bernstein Capital Management LLC’s holdings, making the stock its 19th biggest position. Silverberg Bernstein Capital Management LLC’s holdings in Teva Pharmaceutical Industries were worth $1,508,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of TEVA. Sanctuary Advisors LLC boosted its position in Teva Pharmaceutical Industries by 1.9% during the 3rd quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company’s stock worth $601,000 after acquiring an additional 664 shares during the period. Sequoia Financial Advisors LLC grew its position in Teva Pharmaceutical Industries by 0.7% during the third quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company’s stock valued at $2,025,000 after purchasing an additional 805 shares in the last quarter. DGS Capital Management LLC lifted its position in Teva Pharmaceutical Industries by 6.8% in the 3rd quarter. DGS Capital Management LLC now owns 13,627 shares of the company’s stock worth $246,000 after buying an additional 872 shares in the last quarter. Smithfield Trust Co boosted its stake in shares of Teva Pharmaceutical Industries by 55.7% during the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after buying an additional 980 shares during the period. Finally, Signaturefd LLC grew its holdings in shares of Teva Pharmaceutical Industries by 16.9% during the 3rd quarter. Signaturefd LLC now owns 7,583 shares of the company’s stock valued at $137,000 after acquiring an additional 1,094 shares in the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Price Performance

NYSE TEVA opened at $21.32 on Wednesday. The company has a market cap of $24.15 billion, a P/E ratio of -25.08, a P/E/G ratio of 0.99 and a beta of 0.73. Teva Pharmaceutical Industries Limited has a 1 year low of $10.83 and a 1 year high of $22.80. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. The company has a fifty day simple moving average of $18.97 and a 200 day simple moving average of $18.11.

Insider Activity

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the sale, the director now owns 695,000 shares in the company, valued at $15,296,950. The trade was a 29.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Christine Fox sold 19,388 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the transaction, the executive vice president now owns 44,104 shares of the company’s stock, valued at $744,034.48. This trade represents a 30.54 % decrease in their position. The disclosure for this sale can be found here. 0.55% of the stock is currently owned by company insiders.

Analyst Ratings Changes

TEVA has been the subject of a number of research reports. Barclays lifted their price objective on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company an “overweight” rating in a research report on Wednesday, December 18th. JPMorgan Chase & Co. boosted their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, October 21st. Finally, StockNews.com lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $20.88.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.